Schwyz-based Liom, an innovator in non-invasive biomarker monitoring and the developer of a non-invasive glucose-monitoring wearable, announced a €13.9 million (CHF 13 million) extension of its Series A financing round.
The round was led by previous lead investors, with new participation from Red Bull Ventures, Marc Maurer (former co-CEO of On Running), Melih Odemis (former co-founder and CTO of Yemeksepeti), Alejo Costa Ribalta, partner of venture capital firm CRB Health Tech and former senior executive of Philips and GE Healthcare – bringing its total Series A to €40.8 million (CHF 38 million) and its total funding to date to €67.6 million (CHF 63 million).
“Now, we can also be sure that we’ve not only proven the method, but we had the right team and the right amount of luck to generate the required breakthrough innovations in order to bring our platform into a wearable-fitting form-factor,” says Leo Grünstein, founder and CEO of Liom.
In 2025, European HealthTech startups focusing on wearables, biosensing, and preventive care have attracted notable venture capital, reflecting investor confidence in technologies that deliver continuous health insights beyond traditional clinical settings.
For example, Sava Technologies Ltd., a London-based MedTech innovator in real-time molecular wearable sensors, raised €16.6 million in Series A to advance regulatory approval and commercialisation of its next-generation device, bringing its total funding to nearly €28 million. In adjacent preventive care domains, Lucis secured €7.2 million in Seed funding to expand its biomarker-based health analytics platform across Europe, and GlycanAge raised €7.4 million to scale its glycan-based diagnostics for preventive ageing care.
Together, these 2025 rounds illustrate a funding climate where roughly €31 million is being allocated toward startups developing continuous monitoring, personalised metabolic insight tools, and preventive diagnostics that sit alongside Liom’s non-invasive glucose wearable innovation.
“Our miniaturisation breakthrough significantly increases light throughput versus current state-of-the-art solutions – even outperforming table-sized lab-scale devices by 12x – and with that unlocks prior unseen performance, a >24h battery life, smartwatch sizing and manufacturability at scale” Grünstein adds.
Founded in 2017 by Leo Grünstein, Liom Health (formerly Spiden) is a Swiss HealthTech startup innovating preventive and personalised health monitoring through a novel wearable that enlightens users with real-time biophysical feedback.
Liom’s first product, expected to launch in 2028, is a non-invasive glucose-monitoring wearable that offers a comprehensive view of metabolic health.
The new capital follows Liom’s recent breakthrough in miniaturising its proprietary Raman spectroscopy platform, having proven its ability to measure glucose non-invasively and as the world’s only company calibration-free, i.e. requiring no needles to calibrate whatsoever, on over 130 subjects in the course of the past years.
Liom is also welcoming Marc Maurer, former co-CEO of On Running – a Swiss success story valued at more than €11.8 billion (CHF 11 billion) – as both investor and Board member. Marc brings expertise in product, consumer value creation, as well as branding and marketing, especially at the intersection of health, fitness and consumer products.
His expertise will support Liom as it shifts from R&D into product development and commercialisation.
Maurer states: “Nutrition and movement are absolutely key to a high quality of life. Having access to glucose measurements through a wearable on your wrist, without the need for a needle, will allow all of us to understand the impact of nutrition and movement on our body much better and therefore live a healthier life. Liom unlocks mass-adoption by consumers & athletes vs current microneedle CGM devices.
“I believe Liom has the potential to disrupt and significantly expand the wearable market that has been created by Apple Watch, Samsung Galaxy Watch, Fitbit, Garmin, Whoop, Oura, etc – yet hasn’t seen sensor-level innovation over the past decade.”
Read the orginal article: https://www.eu-startups.com/2025/12/swiss-wearable-glucose-monitoring-technology-startup-liom-closes-e13-9-million/
